Alex Farrell
Overview
Explore the profile of Alex Farrell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
40
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Clements A, Casillas A, Flores C, Liou H, Toth R, Chauhan S, et al.
Cancer Immunol Res
. 2025 Feb;
PMID: 39982419
Immune checkpoint inhibitors (ICIs) have changed the treatment paradigm for many cancers but have not shown benefit in prostate cancer (PCa). Chronic inflammation contributes to the immunosuppressive prostate tumor microenvironment...
2.
Alvero A, Wu S, Farrell A, Kim S, Wallbillich J, Winer I, et al.
Gynecol Oncol
. 2025 Feb;
194:71-79.
PMID: 39970633
Objective: The purpose of this study was to evaluate the transcriptomic profile of BRCA1 mutant (BRCA1mut) and BRCA2 mutant (BRCA2mut) HGSOC compared to homologous recombination wild-type (HRwt) tumors utilizing the...
3.
Mittal P, Battaglin F, Baca Y, Xiu J, Farrell A, Soni S, et al.
Int J Cancer
. 2024 Dec;
156(8):1583-1593.
PMID: 39740007
Myeloid cell leukemia 1 (MCL-1) is a member of the B-cell lymphoma 2 protein family and has anti-apoptotic functions. Deregulation of MCL-1 has been reported in several cancers, including lung...
4.
Xue E, Bracken-Clarke D, Krause H, Adeyelu T, Evans M, Akbulut D, et al.
Cancers (Basel)
. 2024 Dec;
16(23).
PMID: 39682120
Olfactory neuroblastoma (ONB), sinonasal undifferentiated carcinoma (SNUC), and sinonasal neuroendocrine carcinoma (SNEC) are rare malignancies arising from the sinonasal tract with limited therapeutic options. The expression of the somatostatin receptor...
5.
Clements A, Casillas A, Flores C, Liou H, Toth R, Chauhan S, et al.
bioRxiv
. 2024 Nov;
PMID: 39484473
Immunotherapy has changed the treatment paradigm for many types of cancer, but immune checkpoint inhibitors (ICIs) have not shown benefit in prostate cancer (PCa). Chronic inflammation contributes to the immunosuppressive...
6.
Watson A, Krause H, Elliott A, Farrell A, Liu S, Ma P, et al.
Clin Lung Cancer
. 2024 Oct;
25(8):712-722.e1.
PMID: 39384504
Background: Gene copy number gain (CNG) is a continuous variable. The relevant cutpoint for HER2, KRAS and MET CNG in non-mall cell lung cancer remains uncertain. As de novo driver...
7.
Singh H, Xiu J, Kapner K, Yuan C, Narayan R, Oberley M, et al.
Clin Cancer Res
. 2024 Sep;
30(21):4932-4942.
PMID: 39283131
Purpose: Transcriptional profiling of pancreatic cancers has defined two main transcriptional subtypes: classical and basal. Initial data suggest shorter survival for patients with basal tumors and differing treatment sensitivity to...
8.
Malla M, Deshmukh S, Wu S, Samec T, Olevian D, El Naili R, et al.
Cancer Gene Ther
. 2024 Aug;
31(10):1547-1558.
PMID: 39174744
The expression of the protein Mesothelin (MSLN) is highly variable in several malignancies, including colorectal cancer (CRC), and high levels are associated with aggressive clinicopathological features and worse patient survival....
9.
Meagher M, Krause H, Elliott A, Farrell A, Antonarakis E, Bastos B, et al.
Cancer Med
. 2024 Apr;
13(7):e7148.
PMID: 38558536
Background: Non-canonical WNT family (WNT5A pathway) signaling via WNT5A through ROR1 and its partner, ROR2, or Frizzled2 (FZD2) is linked to processes driving tumorigenesis and therapy resistance. We utilized a...
10.
Khushman M, Toboni M, Xiu J, Manne U, Farrell A, Lou E, et al.
Clin Cancer Res
. 2024 Feb;
30(9):1906-1915.
PMID: 38350001
Purpose: The response to immune checkpoint inhibitors (ICI) in deficient mismatch repair (dMMR) colorectal cancer and endometrial cancer is variable. Here, we explored the differential response to ICIs according to...